Prof. Han specializes in treating patients with cancers of the genitourinary system, including those affecting the bladder, kidney, prostate, adrenal glands, ureter, urethra, testis, epididymis, spermatic cord, and penis. His focus is particularly on comprehensive treatment for kidney tumors, penile tumors, and retroperitoneal tumors. He is skilled in various minimally invasive surgical treatments, such as laparoscopic and robot-assisted laparoscopic surgeries. Additionally, he focuses on integrated, multi-approach strategies such as immunotherapy, chemotherapy and surgical interventions for advanced or relapsed penile cancer.

Prof. Han performs both laparoscopic and open procedures to treat these cancers, often adopting a multi-disciplinary team approach with the integration of expertise from medical oncology and/or radiation oncology. He has also pursued technical innovations that have transformed the management of these cancers, including open inguinal lymphadenectomy, laparoscopic and robot-assisted laparoscopic kidney-sparing partial nephrectomy, complex surgeries for difficult cases such as T1b tumors, renal-type tumors, and hilar tumors, as well as laparoscopic retroperitoneal lymph node dissection.

Prof. Han possesses specialized expertise in managing rare urologic cancers, including penile cancer, as well as performing salvage procedures for recurrent kidney cancers that have not responded to initial treatments such as surgery or other therapies. Over the past five years, he has investigated the combination of chemotherapy, immunotherapy, and anti-EGFR monoclonal antibodies for treating patients with N2-N3 stage penile cancer, yielding promising results. The objective response rate exceeds 75%, with a pathological complete response of approximately 40%, significantly enhancing patients' overall survival. His research on penile cancer has been cited many times in the EAU and NCCN guidelines. Prof. Han and his team have over 200 cases of combined immunotherapy for penile cancer, showing promising survival results globally.

Kidney cancer and penile cancer

Prof. Han trained in the Tong Ji University School of Medicine. He acquired M.D in Tong Ji University School of Medicine and completed his Residency training in Tong Ji hospital.

1. Xiong L, Shan X, Ma H, et al. First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study. J Natl Compr Canc Netw. 2024;23(1):e247074. doi:10.6004/jnccn.2024.7074

2. Yang JF, Xing X, Luo L, et al. Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8+ T cell metabolic fitness and function in tumors. Sci Immunol. 2023;8(87):eabq2424. doi:10.1126/sciimmunol.abq2424

3. Wei L, Li Z, Guo S, et al. Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy. Cancer. 2024;130(9):1650-1662. doi:10.1002/cncr.35177

4. Xu DM, Zhuang XY, Ma HL, et al. Altered tumor microenvironment heterogeneity of penile cancer during progression from non-lymphatic to lymphatic metastasis. Cancer Med. 2024;13(14):e70025. doi:10.1002/cam4.70025

5. Liu T, Yue X, Chen X, et al. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma. Cell Oncol (Dordr). 2024;47(4):1277-1294. doi:10.1007/s13402-024-00927-9

6. Wei L, Huang K, Han H, Liu RY. Human Papillomavirus Infection in Penile Cancer: Multidimensional Mechanisms and Vaccine Strategies. Int J Mol Sci. 2023;24(23):16808. doi:10.3390/ijms242316808

7. Yan R, Ma H, Jiang L, et al. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer. BJU Int. 2023;131(2):198-207. doi:10.1111/bju.15828

8. Tan X, Cai T, Wang Y, Wu Z, Zhou Q, Guo S, Li J, Yuan G, Liu Z, Li Z, Liu Z, Tang Y, Zou Y, Luo S, Qin Z, Zhou F, Lin C, Han H, Yao K. Regional lymph node mapping in patients with penile cancer undergoing radical inguinal lymph node dissection - a retrospective cohort study. Int J Surg. 2024 May 1;110(5):2865-2873. doi: 10.1097/JS9.0000000000001160.

9. Zhou QH, Deng CZ, Li ZS, Chen JP, Yao K, Huang KB, Liu TY, Liu ZW, Qin ZK, Zhou FJ, Huang W, Han H, Liu RY. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Cell Death Dis. 2018 Jun 7;9(6):684. doi: 10.1038/s41419-018-0736-1.

10. Li ZS, Ornellas AA, Schwentner C, Li X, Chaux A, Netto G, Burnett AL, Tang Y, Geng J, Yao K, Chen XF, Wang B, Liao H, Liu N, Chen P, Lei YH, Mi QW, Rao HL, Xiao YM, Wang QL, Qin ZK, Liu ZW, Li YH, Zou ZJ, Luo JH, Li H, Han H, Zhou FJ. A modified clinicopathological tumor staging system for survival prediction of patients with penile cancer. Cancer Commun (Lond). 2018 Nov 23;38(1):68. doi: 10.1186/s40880-018-0340-x.